Super Vidalista: Uses, dosage, side effects, warnings & patient reviews

What is Super Vidalista?

Super Vidalista is a dual-component oral tablet containing two active pharmaceutical ingredients: tadalafil and dapoxetine hydrochloride. It is formulated to address two distinct male sexual health conditions concurrently in patients diagnosed with both.

Active Ingredients and Mechanism of Action

Tadalafil (20 mg): A phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED). It works by relaxing blood vessels in the penis, facilitating increased blood flow necessary for achieving an erection upon sexual stimulation.

Dapoxetine Hydrochloride (60 mg): A short-acting selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of premature ejaculation (PE). It modulates serotonin levels in the central nervous system, which is involved in the control of the ejaculatory reflex.

Regulatory Status and Product Origin

It is critical to note that Super Vidalista is a foreign generic medication. Dapoxetine is not an FDA-approved drug for any indication in the United States. Consequently, the fixed-dose combination of tadalafil and dapoxetine (Super Vidalista) is not authorized for sale or medical use in the U.S. by the FDA. This product is sometimes marketed as an enhanced version of the single-agent Vidalista, which contains only tadalafil.

How to Take Super Vidalista

Administration of Super Vidalista must follow a healthcare provider’s specific prescription and instructions. The information below represents general clinical guidance.

Dosage and Administration

The standard dosage of Super Vidalista is one tablet taken orally. The tablet contains a fixed dose of 20 mg tadalafil and 60 mg dapoxetine.

The tablet should be swallowed whole with a glass of water. It may be taken with or without food; however, consumption with a high-fat meal may delay the absorption of tadalafil.

Timing and Frequency

Super Vidalista is taken on an “as-needed” basis prior to anticipated sexual activity.

• Timing: The tablet should be taken approximately 1 to 3 hours before sexual activity. This allows sufficient time for both components to reach effective plasma concentrations. Dapoxetine requires this lead time for optimal effect on the ejaculatory reflex.
• Frequency: Only one tablet should be taken within a 24-hour period. The long half-life of tadalafil (up to 36 hours of effect for ED) does not permit more frequent dosing of this combination due to the dapoxetine component.

For insights on planning medication timing for sexual activity, a resource on timing tadalafil-based medications may be relevant.

Important Precautions

• Sexual stimulation is required for the tadalafil component to be effective for erectile function.
• The tablet should not be split, crushed, or chewed, as this may alter the drug release profile, particularly for dapoxetine.
• This medication is not intended for continuous daily use for the treatment of PE; it is an on-demand therapy.

Side Effects of Super Vidalista

Adverse reactions associated with Super Vidalista are attributable to the individual or combined effects of tadalafil and dapoxetine. The incidence and severity may vary. A general framework for understanding side effects of ED treatments is available in this urologist’s guide.

What is Super Vidalista Used For?

Super Vidalista is prescribed for adult men who are diagnosed with both erectile dysfunction (ED) and premature ejaculation (PE). It is a dual-therapy option intended to address these two conditions simultaneously with a single on-demand tablet.

Primary Indications

• Erectile Dysfunction (ED): The tadalafil component is indicated for the treatment of ED, which is the recurrent inability to achieve or maintain an erection sufficient for satisfactory sexual performance.
• Premature Ejaculation (PE): The dapoxetine component is indicated for the treatment of PE, which is characterized by ejaculation that always or nearly always occurs prior to or within about one minute of vaginal penetration (lifelong PE), or a clinically significant reduction in latency time often ≤3 minutes (acquired PE), and the inability to delay ejaculation on all or nearly all vaginal penetrations, which causes negative personal consequences.

Important Considerations

This medication is not a first-line treatment for either condition individually. It is reserved for cases where a patient has been formally diagnosed with both ED and PE by a healthcare professional. The use of dapoxetine for PE is not an approved indication in all countries, including the United States.

Important Safety Concerns and Considerations

Non-FDA Approved Status and Dapoxetine

The primary concern with Super Vidalista is its regulatory status. Dapoxetine hydrochloride is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of premature ejaculation or any other condition. Consequently, the fixed-dose combination product Super Vidalista is not an FDA-authorized medication. Its safety, efficacy, and manufacturing standards have not been evaluated by the FDA against U.S. regulatory requirements.

Absolute Contraindication with Nitrates

Tadalafil, a PDE5 inhibitor, potently amplifies the vasodilatory and blood-pressure-lowering effects of organic nitrates (e.g., nitroglycerin) and nitric oxide donors. This interaction can lead to a profound and life-threatening drop in blood pressure. The co-administration of Super Vidalista with any nitrate medication is strictly prohibited.

Risk of Serotonin Syndrome

Dapoxetine is a serotonin reuptake inhibitor. Concomitant use with other serotonergic drugs (e.g., MAOIs, SSRIs, SNRIs, tricyclic antidepressants, triptans, tramadol) significantly increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic hyperactivity, and altered mental status.

Cardiovascular and Cerebrovascular Risk

Sexual activity carries a degree of cardiac risk. Tadalafil produces systemic vasodilation and a mild, transient decrease in blood pressure. This medication is contraindicated in patients for whom sexual activity is inadvisable due to significant underlying cardiovascular pathology (e.g., unstable angina, recent MI, severe heart failure, uncontrolled arrhythmias). Dapoxetine is associated with syncope and orthostatic hypotension, posing additional risk.

Quality and Sourcing Concerns

As a non-FDA-approved product, Super Vidalista is not legally marketed through licensed U.S. pharmacies. Products obtained from international or online sources may be counterfeit, substandard, or adulterated. They may contain incorrect doses, wrong active ingredients, or harmful contaminants. There is no regulatory assurance of product quality, stability, or purity. General warnings about such products are discussed in a resource on unregulated ED medications.

Critical Warnings for Super Vidalista Use

Cardiovascular and Cerebrovascular Events

The use of PDE5 inhibitors, including tadalafil, has been associated in rare instances with serious cardiovascular events such as myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, and transient ischemic attack. These events often occur in patients with pre-existing cardiovascular risk factors, during or shortly after sexual activity. A thorough cardiovascular assessment is recommended prior to prescribing any therapy for ED.

Hypotension and Syncope

Dapoxetine can cause significant orthostatic hypotension, leading to dizziness, lightheadedness, and syncope (fainting). This risk is increased with concomitant use of alcohol or other CNS depressants. Patients should be advised to rise slowly from a sitting or lying position, and to avoid situations where injury could occur from syncope.

Mood and Behavior Changes

SSRIs, including dapoxetine, may increase the risk of suicidal ideation and behavior in young adults under age 25, particularly during initial treatment or dose changes. Patients should be monitored for the emergence of agitation, irritability, unusual changes in behavior, or worsening of depression.

Prolonged Erection and Priapism

PDE5 inhibitors, including tadalafil, can lead to erections lasting more than 4 hours (priapism). This condition requires immediate medical intervention to avoid permanent damage to penile tissues and long-term erectile dysfunction.

Sexually Transmitted Infections

This medication does not protect against sexually transmitted infections (STIs), including HIV. The need for protective measures should be considered.

Super Vidalista Dosage Information

Dosage must be individualized by a qualified healthcare professional based on diagnosis, patient health status, and concurrent medications. The following represents standard dosing information for the fixed-dose combination.

Dose Adjustment Considerations

• Initiation of Therapy: A healthcare provider may recommend initiating treatment with single-agent therapies (separate tadalafil and/or dapoxetine) to assess individual tolerance before using the fixed-dose combination.
• Renal or Hepatic Impairment: The safety of the fixed-dose combination in patients with significant renal or hepatic impairment has not been established. Use is not recommended in patients with severe renal insufficiency (CrCl < 30 mL/min) or severe hepatic impairment (Child-Pugh Class C).
• Elderly Patients: Caution is advised. Dose adjustment may be necessary but is limited by the fixed-dose formulation.

Important Administration Notes

• Do not exceed one tablet per day.
• The tablet should be swallowed whole. Do not crush, split, or chew.
• The medication is intended for use “as-needed” and is not for continuous daily administration.
• Sexual stimulation is required for the erectile response.

Drug Interactions with Super Vidalista

Super Vidalista has a significant potential for clinically important drug interactions due to its dual components. A comprehensive review of all concomitant medications (prescription, over-the-counter, and herbal) is mandatory before use.

Additional Information

Storage and Handling

Store Super Vidalista tablets at room temperature (between 15°C and 30°C or 59°F and 86°F), in a tightly closed container, protected from light, moisture, and excessive heat. Keep all medications out of the reach of children and pets.

Cost and Accessibility Considerations

As a non-FDA-approved generic medication, Super Vidalista is not available through licensed U.S. pharmacies. It may be marketed and sold through international or online outlets. Prices and availability vary widely and are not regulated. Patients should be aware that purchasing medications from such sources carries substantial risks related to product authenticity, quality, and safety, as previously noted in the Concerns section.

Reporting Side Effects

If you experience a side effect while using any medication, it is important to inform your healthcare provider. For medications not approved in your country, reporting to local health authorities may still be possible and contributes to post-market surveillance. In the U.S., adverse events for any drug can be reported to the FDA MedWatch program.

References and Medical Sources

1. U.S. Food and Drug Administration (FDA). Cialis (tadalafil) Prescribing Information. [Revised 2011]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf
2. European Medicines Agency (EMA). Priligy (dapoxetine) Annex I: Summary of Product Characteristics. [Last updated 2020]. https://www.ema.europa.eu/en/medicines/human/referrals/priligy
3. American Urological Association (AUA). Pharmacologic Management of Premature Ejaculation (2019). https://www.auanet.org/documents/Guidelines/Archive/Premature-Ejaculation.pdf
4. MedlinePlus. Tadalafil. U.S. National Library of Medicine. https://medlineplus.gov/druginfo/meds/a604008.html

Disclaimer: The information on this site is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult with a doctor or other qualified healthcare professional before making any decisions about your health.